Epidemiology of Acute Heart Failure in Critically Ill Patients with COVID-19: An Analysis from the Critical Care Cardiology Trials Network. | Epidemiology of Acute Heart Failure in Critically Ill Patients With COVID-19: An Analysis From the Critical Care Cardiology Trials Network.
Epidemiology of Acute Heart Failure in Critically Ill Patients with COVID-19: An Analysis from the Critical Care Cardiology Trials Network. Epidemiology of Acute Heart Failure in Critically Ill Patients With COVID-19: An Analysis From the Critical Care Cardiology Trials Network.
- 2022
Available online from MWHC library: 1995 - present
BACKGROUND: Acute heart failure (HF) is an important complication of coronavirus disease 2019 (COVID-19) and has been hypothesized to relate to inflammatory activation. CONCLUSIONS: Among critically ill COVID-19 patients, acute HF is distinguished more by biomarkers of myocardial injury and hemodynamic stress than by biomarkers of inflammation. Copyright (c) 2022 The Authors. Published by Elsevier Inc. All rights reserved. METHODS: We evaluated consecutive intensive care unit (ICU) admissions for COVID-19 across 6 centers in the Critical Care Cardiology Trials Network, identifying patients with vs. without acute HF. Acute HF was sub-classified as "de novo" vs. "acute-on-chronic" based on the absence or presence of prior HF. Clinical features, biomarker profiles, and outcomes were compared. RESULTS: Among 901 COVID-19 ICU admissions, 80 (8.9%) had acute HF, including 18 (2.0%) with classic cardiogenic shock (CS) and 37 (4.1%) with vasodilatory CS. The majority (n=45) were de novo HF presentations. Compared to patients without acute HF, those with acute HF had higher cardiac troponin (cTn) and natriuretic peptides, and similar inflammatory biomarkers; patients with de novo HF had the highest cTn. Notably, among critically ill patients with COVID-19, illness severity (median SOFA, 8 [IQR, 5-10] vs. 6 [4-9]; p=0.025) and mortality (43.8% vs. 32.4%; p=0.040) were modestly higher in patients with vs. without acute HF.
English
10.1016/j.cardfail.2021.12.020 [doi] PMC8762923 [pmc] S1071-9164(22)00007-0 [pii]
*Cardiology
*COVID-19
*Heart Failure
Biomarkers
COVID-19/ep [Epidemiology]
Critical Care
Critical Illness/ep [Epidemiology]
Heart Failure/di [Diagnosis]
Heart Failure/ep [Epidemiology]
Heart Failure/th [Therapy]
Hospital Mortality
Humans
Intensive Care Units
Shock, Cardiogenic/di [Diagnosis]
Shock, Cardiogenic/ep [Epidemiology]
Shock, Cardiogenic/th [Therapy]
Troponin
MedStar Heart & Vascular Institute
Journal Article
Available online from MWHC library: 1995 - present
BACKGROUND: Acute heart failure (HF) is an important complication of coronavirus disease 2019 (COVID-19) and has been hypothesized to relate to inflammatory activation. CONCLUSIONS: Among critically ill COVID-19 patients, acute HF is distinguished more by biomarkers of myocardial injury and hemodynamic stress than by biomarkers of inflammation. Copyright (c) 2022 The Authors. Published by Elsevier Inc. All rights reserved. METHODS: We evaluated consecutive intensive care unit (ICU) admissions for COVID-19 across 6 centers in the Critical Care Cardiology Trials Network, identifying patients with vs. without acute HF. Acute HF was sub-classified as "de novo" vs. "acute-on-chronic" based on the absence or presence of prior HF. Clinical features, biomarker profiles, and outcomes were compared. RESULTS: Among 901 COVID-19 ICU admissions, 80 (8.9%) had acute HF, including 18 (2.0%) with classic cardiogenic shock (CS) and 37 (4.1%) with vasodilatory CS. The majority (n=45) were de novo HF presentations. Compared to patients without acute HF, those with acute HF had higher cardiac troponin (cTn) and natriuretic peptides, and similar inflammatory biomarkers; patients with de novo HF had the highest cTn. Notably, among critically ill patients with COVID-19, illness severity (median SOFA, 8 [IQR, 5-10] vs. 6 [4-9]; p=0.025) and mortality (43.8% vs. 32.4%; p=0.040) were modestly higher in patients with vs. without acute HF.
English
10.1016/j.cardfail.2021.12.020 [doi] PMC8762923 [pmc] S1071-9164(22)00007-0 [pii]
*Cardiology
*COVID-19
*Heart Failure
Biomarkers
COVID-19/ep [Epidemiology]
Critical Care
Critical Illness/ep [Epidemiology]
Heart Failure/di [Diagnosis]
Heart Failure/ep [Epidemiology]
Heart Failure/th [Therapy]
Hospital Mortality
Humans
Intensive Care Units
Shock, Cardiogenic/di [Diagnosis]
Shock, Cardiogenic/ep [Epidemiology]
Shock, Cardiogenic/th [Therapy]
Troponin
MedStar Heart & Vascular Institute
Journal Article